218 related articles for article (PubMed ID: 31188484)
1. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection.
Keikha M; Eslami M; Yousefi B; Ghasemian A; Karbalaei M
J Cell Physiol; 2019 Dec; 234(12):21460-21470. PubMed ID: 31188484
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
Banga Ndzouboukou JL; Lei Q; Ullah N; Zhang Y; Hao L; Fan X
Helicobacter; 2021 Feb; 26(1):e12758. PubMed ID: 33259676
[TBL] [Abstract][Full Text] [Related]
3. Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on
Guo L; Yang H; Tang F; Yin R; Liu H; Gong X; Wei J; Zhang Y; Xu G; Liu K
Front Cell Infect Microbiol; 2017; 7():349. PubMed ID: 28824883
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune responses induced by Helicobacter pylori improve the prognosis of gastric carcinoma.
Xue LJ; Su QS; Yang JH; Lin Y
Med Hypotheses; 2008; 70(2):273-6. PubMed ID: 17681432
[TBL] [Abstract][Full Text] [Related]
5. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation.
Prinz C; Schöniger M; Rad R; Becker I; Keiditsch E; Wagenpfeil S; Classen M; Rösch T; Schepp W; Gerhard M
Cancer Res; 2001 Mar; 61(5):1903-9. PubMed ID: 11280745
[TBL] [Abstract][Full Text] [Related]
6. Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils.
Guo L; Yin R; Xu G; Gong X; Chang Z; Hong D; Liu H; Ding S; Han X; Li Y; Tang F; Liu K
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28851031
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa.
Lamarque D; Gilbert T; Roudot-Thoraval F; Deforges L; Chaumette MT; Delchier JC
Eur J Gastroenterol Hepatol; 1999 Jul; 11(7):721-6. PubMed ID: 10445790
[TBL] [Abstract][Full Text] [Related]
8. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.
Hatzifoti C; Roussel Y; Harris AG; Wren BW; Morrow JW; Bajaj-Elliott M
Helicobacter; 2006 Apr; 11(2):113-22. PubMed ID: 16579841
[TBL] [Abstract][Full Text] [Related]
9. The design of vaccines against Helicobacter pylori and their development.
Del Giudice G; Covacci A; Telford JL; Montecucco C; Rappuoli R
Annu Rev Immunol; 2001; 19():523-63. PubMed ID: 11244046
[TBL] [Abstract][Full Text] [Related]
10. A novel design of a multi-antigenic, multistage and multi-epitope vaccine against Helicobacter pylori: An in silico approach.
Meza B; Ascencio F; Sierra-Beltrán AP; Torres J; Angulo C
Infect Genet Evol; 2017 Apr; 49():309-317. PubMed ID: 28185986
[TBL] [Abstract][Full Text] [Related]
11. Protection against Helicobacter pylori infection by a trivalent fusion vaccine based on a fragment of urease B-UreB414.
Wang L; Liu XF; Yun S; Yuan XP; Mao XH; Wu C; Zhang WJ; Liu KY; Guo G; Lu DS; Tong WD; Wen AD; Zou QM
J Microbiol; 2010 Apr; 48(2):223-8. PubMed ID: 20437155
[TBL] [Abstract][Full Text] [Related]
12. Protection Against
Pan X; Ke H; Niu X; Li S; Lv J; Pan L
Front Immunol; 2018; 9():1003. PubMed ID: 29867978
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination.
Prinz C; Hafsi N; Voland P
Trends Microbiol; 2003 Mar; 11(3):134-8. PubMed ID: 12648945
[TBL] [Abstract][Full Text] [Related]
14. New acquisitions in Helicobacter pylori characteristics.
Figura N; Vindigni C; Presenti L; Carducci A
Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S254-8. PubMed ID: 10077748
[TBL] [Abstract][Full Text] [Related]
15. Serological response to Helicobacter pylori recombinant antigens in Chilean infected patients with duodenal ulcer, non-ulcer dyspepsia and gastric cancer.
Opazo P; Müller I; Rollán A; Valenzuela P; Yudelevich A; García-de la Guarda R; Urra S; Venegas A
APMIS; 1999 Dec; 107(12):1069-78. PubMed ID: 10660136
[TBL] [Abstract][Full Text] [Related]
16. Serum antibody positivity for distinct Helicobacter pylori antigens in benign and malignant gastroduodenal disease.
Schumann C; Triantafilou K; Rasche FM; Möricke A; Vogt K; Triantafilou M; Hahn P; Schneider EM; Lepper PM
Int J Med Microbiol; 2006 Aug; 296(4-5):223-8. PubMed ID: 16600680
[TBL] [Abstract][Full Text] [Related]
17. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country.
Mitchell HM; Hazell SL; Li YY; Hu PJ
Am J Gastroenterol; 1996 Sep; 91(9):1785-8. PubMed ID: 8792699
[TBL] [Abstract][Full Text] [Related]
18. Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases.
Chomvarin C; Ottiwet O; Hahnvajanawong C; Intapan PM; Wongwajana S
Int J Infect Dis; 2009 Sep; 13(5):647-54. PubMed ID: 19233700
[TBL] [Abstract][Full Text] [Related]
19. The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia.
Arnold IC; Hitzler I; Engler D; Oertli M; Agger EM; Müller A
J Immunol; 2011 Jun; 186(11):6165-72. PubMed ID: 21518972
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of Western Blot method for the detection of antibodies to Helicobacter pylori antigens in patients with gastric carcinoma and cases with epigastric complaints].
Güdücüoğlu H; Berktaş M; Bozkurt H; Toka Ozer T; Bulut G; Oztürk O; Ilhan M
Mikrobiyol Bul; 2010 Jan; 44(1):21-8. PubMed ID: 20455395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
